research A Definitive Role of Ornithine Decarboxylase in Photocarcinogenesis
Inhibiting ODC can prevent UV-induced skin cancer.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research Alopecia Areata: Current Understanding and Management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Cutaneous Adverse Events to Systemic Antineoplastic Therapies: A Retrospective Study in a Public Oncologic Hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research Non-Scarring Alopecia in Females: A Comprehensive Review
Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.
research An ERK-Dependent Molecular Switch Antagonizes Fibrosis and Promotes Regeneration in Spiny Mice
High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.
research Clinical Snippets: Dermatological Findings and Insights
A hormone affects hair growth, certain molecules may prevent skin damage, a skin disease is linked to immune cells, glycerol helps skin hydration, and psoriasis treatment trials need improvement.
research Molecular Targeted Agents and Biologic Therapies for Non-Small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research Drug Repurposing Against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
research The Ophthalmological Complications of Targeted Agents in Cancer Therapy: What Do We Need to Know as Ophthalmologists?
Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens Against E2F1-Driven Melanoma Progression
Tadalafil and Finasteride may help treat aggressive melanoma.
research Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution, And Tumor-Initiating Cells
Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
Afatinib often causes skin problems that need proactive management.
research When Bugs and Drugs Conspire: Driving Acneiform Skin Toxicity
Certain cancer drugs interact with skin bacteria to cause acne-like rashes.
research Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research Multiple Skin Cancers in a Patient Within 1 Year of Allogeneic Hematopoietic Cell Transplant for Chronic Lymphocytic Leukemia
A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.
research Gefitinib: An Adverse Effects Profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research Skin Toxicity of Anti-Cancer Therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research High Response Rate to Bexxar in Advanced Stage Prior Treatment-Resistant Follicular Lymphoma
Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
research Oral Tofacitinib in Moderate and Severe Alopecia Areata: Case Series of 14 Patients
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
research Hair Manifestations of Systemic Disease
Hair changes can indicate systemic diseases or medication effects.
research Delayed Onset Perforating Folliculitis Associated with Sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research Delayed-Onset Pachyonychia Congenita Caused by a Novel Mutation in the V2 Domain of Keratin 6B
A new mutation in the K6b gene caused a girl's late-appearing nail condition.
research Effects of Adenosine Triphosphate on Vandetanib-Induced Skin Damage in Rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research Vandetanib-Associated Alopecia Areata in a Patient with Metastatic Medullary Thyroid Cancer
A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.